Teva Pharmaceuticals USA Inc. is taking the Biden administration to court over its drug price negotiation program, days ...

Klinge Biopharma GmbH (Klinge) holds the exclusive global commercialization rights for FYB203, Formycon's biosimilar candidate to ...

New partnerships aim to expand Teva’s biosimilar portfolio and enhance access to high-cost biologics across key markets.

Teva Pharmaceuticals challenges the Inflation Reduction Act, arguing CMS's drug pricing policies harm generics, biosimilars, ...

Teva Pharmaceuticals International GmbH, a subsidiary of Teva, has entered into a strategic collaboration with Klinge Biopharma GmbH and Formycon AG for the semi-exclusive commercialization of FYB203, ...

Shares of Catalyst Pharmaceuticals CPRX gained 16.7% on Wednesday after the company, along with its licensor, SERB, announced that it has entered into a settlement agreement with Teva Pharmaceuticals ...

Teva Pharmaceutical (NYSE:TEVA) has entered into a strategic collaboration with Klinge Biopharma and Formycon AG, for the ...

This collaboration combines Teva’s deep commercial experience in biosimilars and its extensive distribution network and broad sales and marketing reach across Europe, with Formycon’s ...

Like all UK pharma GMs working during the COVID-19 pandemic, Teva’s Kim Innes has found herself leading her company through an unprecedented crisis in one of the worst-hit countries in the world.

South Korea's Celltrion and marketing partner Teva are seeking approval in the drug’s oncology indications. The FDA is not bound to follow the advice of its committees when making regulatory ...

Teva was established as the European commercialisation partner of FYB201, Formycon's biosimilar to ranibizumab (Lucentis).

in line with its Pivot to Growth strategy This collaboration combines Teva’s deep commercial experience in biosimilars and its extensive distribution network and broad sales and marketing reach ...